Whalesbook Logo
Whalesbook
HomeStocksNewsPremiumAbout UsContact Us

Chief Economic Advisor V. Anantha Nageswaran: India's Financial Sector Needs Bolder Risk-Taking, Deeper Focus Than Market Cap

Economy

|

Published on 17th November 2025, 9:43 AM

Whalesbook Logo

Author

Aditi Singh | Whalesbook News Team

Overview

Chief Economic Advisor V. Anantha Nageswaran advised India's financial sector to be bolder and technologically sharper, urging them to avoid focusing on "market capitalization ratios or the volumes of derivatives traded" as misleading indicators. Speaking at the CII Financing Summit 2025, he stressed the need to shift from balance-sheet preservation to deployment, emphasizing long-term development needs and domestic capital in an uncertain global environment.

Chief Economic Advisor V. Anantha Nageswaran: India's Financial Sector Needs Bolder Risk-Taking, Deeper Focus Than Market Cap

Chief Economic Advisor V. Anantha Nageswaran, speaking at the CII Financing Summit 2025, called for a significant shift in India's financial sector's approach to growth and progress. He argued that metrics such as "market capitalization ratios or the volumes of derivatives traded" are misleading indicators and can inadvertently divert domestic savings away from truly productive investments.

Nageswaran urged banks and financial institutions to adopt a more proactive stance, becoming "bolder, technologically sharper and more willing to take calculated risks." He highlighted the current global landscape as one of increased uncertainty, requiring the financial system to serve as a robust source of stability for the nation's ambitious development goals. The advisor emphasized that external financing alone will be insufficient, necessitating a strong reliance on domestic capital.

A key theme was the need to move "from balance-sheet preservation to balance-sheet deployment," supported by patient capital and innovation. This strategic shift is crucial for India to achieve industrial upgrading, leverage its demographic advantages, ensure energy security, and expand its innovation capabilities. Nageswaran cautioned that "business-as-usual financing will not suffice in an era defined by uncertainty and technological discontinuities."

He also referenced global risks, including the potential severity of an AI boom bust, and stressed India's need to build "strategic leverage commensurate with our economic size globally" as supply chains are reshuffled.

While acknowledging the current health of India's banking system, Nageswaran warned against complacency, stating, "We must not mistake strength for readiness." He believes the coming decade will present new challenges, requiring greater support for innovators, deeper bond markets, and a rethinking of financial intermediation in light of advancements like tokenization.

Impact

This advisory signals a potential reorientation of priorities for Indian financial institutions, encouraging greater focus on long-term growth initiatives and calculated risk-taking. It could lead to policy discussions that favour robust domestic capital deployment over speculative market indicators, potentially impacting investment strategies and sector growth. The emphasis on innovation and technology could spur specific areas of the financial market.

Rating: 7/10

Difficult Terms:

Market Capitalization Ratios: A metric indicating the total market value of a publicly traded company's outstanding shares, often used as a proxy for company size and investor sentiment. Nageswaran suggests this is not a true measure of financial health or productive investment.

Volumes of Derivatives Traded: Refers to the total number of contracts in financial derivatives (like options and futures) that have been bought and sold. High volumes can indicate liquidity but also potentially speculative activity that diverts capital from real economic uses.

Productive Investment: Investments made in assets or ventures that contribute to economic growth and generate tangible returns, such as building factories, infrastructure, or engaging in research and development.

Balance-sheet Preservation: A conservative financial strategy focused on protecting assets and minimizing liabilities, often involving avoiding new risks.

Balance-sheet Deployment: An active strategy of using a company's financial resources (assets and capital) to pursue growth opportunities, make investments, and generate returns.

Patient Capital: Long-term funding provided to businesses that is willing to accept lower returns or longer payback periods in exchange for potential future growth and impact. It is often crucial for startups and long-term infrastructure projects.

Tokenization: The process of converting rights to an asset (like real estate, stocks, or bonds) into a digital token on a blockchain, which can facilitate easier trading and fractional ownership.

Intermediation: The role of financial institutions, such as banks, in acting as a go-between for individuals or entities that have surplus funds (savers) and those that need funds (borrowers).


Healthcare/Biotech Sector

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Marksans Pharma Receives UK Approval for Mefenamic Acid Tablets, Boosting Generics Portfolio

Marksans Pharma Receives UK Approval for Mefenamic Acid Tablets, Boosting Generics Portfolio

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

AstraZeneca Pharma India & Sun Pharma Forge Second Brand Partnership for Hyperkalaemia Treatment

AstraZeneca Pharma India & Sun Pharma Forge Second Brand Partnership for Hyperkalaemia Treatment

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Marksans Pharma Receives UK Approval for Mefenamic Acid Tablets, Boosting Generics Portfolio

Marksans Pharma Receives UK Approval for Mefenamic Acid Tablets, Boosting Generics Portfolio

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

AstraZeneca Pharma India & Sun Pharma Forge Second Brand Partnership for Hyperkalaemia Treatment

AstraZeneca Pharma India & Sun Pharma Forge Second Brand Partnership for Hyperkalaemia Treatment


SEBI/Exchange Sector

SEBI Initiates Listing Norms Review, IPO Clarity for NSE Expected

SEBI Initiates Listing Norms Review, IPO Clarity for NSE Expected

SEBI Initiates Listing Norms Review, IPO Clarity for NSE Expected

SEBI Initiates Listing Norms Review, IPO Clarity for NSE Expected